California First National Bancorp (NASDAQ:CFNB) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $15.09 and last traded at $14.95, with a volume of 11,713 shares. The stock had previously closed at $14.75.

CFNB has been the subject of several research analyst reports. TD Securities downgraded California First National Bancorp from a “buy” rating to a “hold” rating and boosted their target price for the stock from $24.00 to $27.00 in a research note on Tuesday, April 26th. Scotiabank reissued a “sector perform” rating and set a $28.00 target price (up previously from $27.00) on shares of California First National Bancorp in a research note on Sunday, May 1st. TheStreet raised California First National Bancorp from a “hold” rating to a “buy” rating in a research note on Monday, May 9th. Finally, RBC Capital Markets downgraded California First National Bancorp from a “sector perform” rating to an “underperform” rating and upped their price objective for the company from $28.00 to $31.00 in a research note on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. California First National Bancorp currently has a consensus rating of “Hold” and a consensus price target of $27.00.

The stock’s 50-day moving average is $14.35 and its 200-day moving average is $14.02. The stock has a market capitalization of $153.67 million and a P/E ratio of 24.96.

California First National Bancorp is a bank holding company. The Company operates through two business segments: CalFirst Leasing and CalFirst Bank. Its primary business is secured financing provided through leasing and financing capital assets, commercial loans acquired through participation in the syndicated commercial loan market, by providing non-recourse loans to third parties secured by leases and equipment, and direct commercial loans.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.